within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC20_Netakimab;

model Netakimab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.2499999999999997e-09,
    adminDuration = 600,
    adminMass = 120 / 1000000,
    adminCount = 1,
    Vd = 0.0057,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0023,
    k12 = 3.222222222222222e-09,
    k21 = 3.222222222222222e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Netakimab</td></tr><tr><td>ATC code:</td><td>L04AC20</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>120</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.0117</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Netakimab is a humanized IgG1 monoclonal antibody targeting interleukin-17A (IL-17A), used for the treatment of autoimmune inflammatory disorders such as moderate-to-severe plaque psoriasis and psoriatic arthritis. It is approved for clinical use in Russia and certain other countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with moderate-to-severe plaque psoriasis and psoriatic arthritis; healthy volunteers and clinical use population; both sexes; typical adult population.</p><h4>References</h4><ol><li><p>Erdes, S, et al., &amp; Ivanov, R (2020). Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. <i>Clinical and experimental rheumatology</i> 38(1) 27–34. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31025924/\">https://pubmed.ncbi.nlm.nih.gov/31025924</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AC20 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Netakimab;
